Cell therapy · Kills target cells · developed by Cogent Biosciences
ACTR707 is an autologous T-cell therapy engineered to express a chimeric receptor combining the CD16 Fc receptor domain with CD28 co-stimulatory signaling. When co-administered with a cancer-specific antibody, ACTR707 T-cells bind the antibody-targeted tumor cells and kill them through cytotoxin release and immune activation. It is studied in lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03189836 | Phase 1 | Lymphoma | Terminated | COGT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lymphoma
See COGT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
COGT catalysts and pipeline →